Meningococcal conjugate vaccines policy update: Booster dose recommendations

Pediatrics

Volumn 128, Issue 6, 2011, Pages 1213-1218

  Brady, Michael T ⁱ   Bernstein, Henry H ⁱ   Byington, Carrie L ⁱ   Edwards, Kathryn M ⁱ   Fisher, Margaret C ⁱ   Glode, Mary P ⁱ   Jackson, Mary Anne ⁱ   Keyserling, Harry L ⁱ   Kimberlin, David W ⁱ   Maldonado, Yvonne A ⁱ   Orenstein, Walter A ⁱ   Schutze, Gordon E ⁱ   Willoughby, Rodney E ⁱ   Bortolussi, Robert ^a   Fischer, Marc A ^b   Gellin, Bruce ^c   Gorman, Richard L ^d   Lee, Lucia ^e   Pratt, R Douglas ^e   Seward, Jane ^b   Starke, Jeffrey R ^f   Swanson, Jack ^g   Tan, Tina Q ^h   more..

^a CANADIAN PAEDIATRIC SOCIETY   (Canada)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c National Vaccine Program Office   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f American Thoracic Society   (United States)

^g Committee on Practice Ambulatory Medicine ^*  (United States)

^h Pediatric Infectious Diseases Society   (United States)

ⁱ NONE

Author keywords

Adolescents; Immunization; Meningitis; Meningococcal vaccine; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ADOLESCENT; AGE; ASPLENIA; CHILD; COMPLEMENT DEFICIENCY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION RISK; MENINGOCOCCOSIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEALTH POLICY; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 83155176172     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2380     Document Type: Review

References (22)

1. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60(3):72-76
2. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1-21
3. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep. 2009;58(37):1042-1043
4. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116(2):496-505
5. American Academy of Pediatrics, Committee on Infectious Diseases. Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students). Pediatrics. 2000;106(6):1500-1504
6. American Academy of Pediatrics, Committee on Infectious Diseases; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Meningococcal disease prevention and control strategies for practice-based physicians. Pediatrics. 1996;97(3):404-412
7. Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193(6):821-828
8. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Hum Vaccin. 2010;6(11):881-887
9. Snape M, Kelly D, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43(11):1387-1394
10. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50(12):1601-1610
11. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128-131
12. Cohn A. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Proceedings of the Advisory Committee on Immunization Practices (ACIP) meeting, Atlanta. June 24, 2009
13. Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadravalent meningococcal vaccine. Pediatr Infect Dis J. 2011;30(6):451-455
14. Cohn A. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Proceedings of the Advisory Committee on Immunization Practices (ACIP) meeting, Atlanta. October 27, 2010
15. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745-1752
16. Rand CM, Schaffer SJ, Humiston SG, et al. Patient-provider communication and human papillomavirus vaccine acceptance. Clin Pediatr (Phila). 2011;50(2):106-113
17. Ortega-Sanchez I. Cost-effectiveness of Meningococcal Vaccination Strategies for Adolescents in the United States. Atlanta, GA: Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; 2010. Available at: www.cdc.gov/vaccines/recs/acip/downloads/mtgslides-oct10/02-3- mening-CostEffect.pdf. Accessed March 29, 2011
18. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003;21(27-30):4437-4447
19. Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MR, Dankert J. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol. 1998;114(3):362-369
20. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun. 2004;72(1):332-337
21. Siberry GK, Williams PL, Lujan-Zilbermann J, et al.; IMPAACT P1065 Protocol Team. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoids conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J. 2010;29(5):391-396
22. Halperin S, Gupta A, Jeanfreau R, et al. Comparison of the safety immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010;28(50):7865-7872